Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
Study Details
Study Description
Brief Summary
Selected patients suspected of having or with prior biopsy proof of malignant disease will be seen in the Urologic Oncology Branch, NCI. Blood samples may be collected at the time of the initial visit and at periodic intervals during the course of the disease. These samples will be stored in the tissue bank of the Urologic Oncology Branch. Aliquots of malignant and normal tissue will be collected at the time of surgery and stored in the tissue bank, Urologic Oncology Branch, NCI. These materials will be used in the research efforts of the Urologic Oncology Branch, NCI.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
Background
Kidney, prostate, bladder, testis and penile cancer account for 22% of cancers diagnosed in the United States and are responsible for 10% of cancer deaths each year in the U.S. Understanding the genes and gene pathways that cause genitourinary malignancies will provide the foundation for the development of targeted therapeutic agents for patients affected with these cancers. Since 1982 investigators in the Urologic Oncology Branch have been studying the genetic basis of urologic cancers. The identification of the genes for cancer of the kidney has led to the approval by the FDA of a number of new agents for patients with advanced disease. It is our goal to study the cancer gene pathways of genitourinary malignancies in order to further understand the cancer gene pathways that cause these diseases.
Objectives
Collection of benign and malignant tissue from patients with known or suspected cancer
Collection of benign and malignant tissue from patients with rare inherited conditions associated with an increased risk for kidney cancer
Determine the molecular genetic differences between normal and tumorigenic tissues
Investigate the categories of genes/ biochemical pathways such as those that influence the cell cycle, angiogenesis, metabolic changes, and metastatic potential
Examine protein expression and bioimmunoassays investigating potential genetic markers
Investigate cellular/biochemical response to existing and novel therapeutic agents
Investigate quality of life in men who have prostate cancer
Investigate molecular genetic basis of urologic malignancies
Examine cell free DNA and circulating tumor DNA for cancer gene mutations
Eligibility
Patients with biopsy-proven malignant disease
Patients suspected of having malignant disease
Patients with known or suspected inherited urologic malignant disorder
Family members (related by blood) of patients who have or are suspected of having an inherited genitourinary disorder or malignancy
Family members of patients with a DNA variant
Design
Patients will be screened for eligibility in the Urologic Oncology Branch Clinic
Blood and urine samples may be obtained
Normal and malignant tissue may be collected from patients undergoing clinically indicated surgical procedures
Basic scientific research will be performed on collected specimens
Patients will have the option to be contacted if a result is detected that would affect their health and they will be given the opportunity to be evaluated and re-tested on an IRB approved protocol if available
Germline and somatic whole genome exome sequencing may be performed
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Family Members Family members (related by blood) of patients who have or are suspected of having a malignant disease or an inherited genitourinary malignant disorder |
|
Patients Patients with biopsy-proven malignant diseases; or patients suspected of having a malignant disease; or patients who have or who are suspected of having an inherited genitourinary malignant disorder |
Outcome Measures
Primary Outcome Measures
- Investigate quality of life in men who have prostate cancer. [on-going]
Prostate cancer patients that have improvement in quality of life
- Investigate molecular genetic basis of urologic malignancies [on-going]
Investigate molecular genetic basis of urologic malignancies
- Investigate cellular/biochemical response to existing and novel therapeutic agents. [on-going]
Collection of blood, urine, saliva, and/or benign and malignant tissue
- Examine protein expression and bioimmunoassays investigating potential genetic markers. [on-going]
Detection and expression analysis of gene(s)
- Determine the molecular genetic differences between normal and tumorigenic tissues. [on-going]
Molecular genetic differences between normal and tumorigenic tissues
- Collection of benign and malignant tissue from patients with rare inherited conditions associated with an increased risk for kidney cancer. [on-going]
Collection of blood, urine, saliva, and/or benign and malignant tissue
- Collection of benign and malignant tissue from patients with known or suspected cancer. [on-going]
Collection of blood, urine, saliva, and/or benign and malignant tissue
Eligibility Criteria
Criteria
-
INCLUSION CRITERIA:
-
Adult and minor patients with biopsy-proven malignant disease
-
Adult and minor patients suspected of having a malignant disease
-
Patients who have or are suspected of having an inherited genitourinary malignant disorder
-
Participants must be >= 2 years of age
-
Family members (related by blood) of patients who have or are suspected of having a malignant disease or an inherited genitourinary malignant disorder
-
All patients and guardians, for adults unable to consent or children younger than 18 years of age, must sign an informed consent document indicating their understanding of the investigational nature and the risks of this study before any protocol related studies are performed. Patients under the age of 18 but who are age 13 or older will be asked to sign an assent document prior to participation.
EXCLUSION CRITERIA:
- Subjects whose co-morbidities preclude surgical intervention.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | National Institutes of Health Clinical Center | Bethesda | Maryland | United States | 20892 |
Sponsors and Collaborators
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: W. Marston Linehan, M.D., National Cancer Institute (NCI)
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 970147
- 97-C-0147
- NCT00897585